Iveda Solutions, Inc.
No enriched coverage for $IVDA in the last 7 days.
No SEC Form 4 filings for $IVDA in the last 30 days.
See all $IVDA insider activity →In biotech pre-market trading, Liminatus Pharma (LIMN) rose about 72% after moving to Nasdaq Capital and receiving an extension to regain minimum bid-price compliance. Iveda Solutions (IVDA) gained about 30% on a partnership announcement with GlobalMed. LENSAR (LNSR) was up about 22% after reporting second-quarter results.
A newly announced partnership is a fresh commercial catalyst that can drive speculative buying and re-rate expectations.
alphai scores every news story that mentions IVDA with an AI model for sentiment and relevance, and aggregates insider trades from Iveda Solutions, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
In biotech pre-market trading, Liminatus Pharma (LIMN) rose about 72% after moving to Nasdaq Capital and receiving an extension to regain minimum bid-price compliance. Iveda Solutions (IVDA) gained about 30% on a partnership announcement with GlobalMed. LENSAR (LNSR) was up about 22% after reporting second-quarter results.
2 min read